Jilin Jian Yisheng Pharmaceutical Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Xiaomin Xue

Algemeen directeur

CN¥717.4k

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	no data
Eigendom CEO	0.5%
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	2.5yrs

Recente managementupdates

Recent updates

Jilin Jian Yisheng Pharmaceutical's (SZSE:002566) Earnings Are Weaker Than They Seem

Apr 25

Lacklustre Performance Is Driving Jilin Jian Yisheng Pharmaceutical Co., Ltd.'s (SZSE:002566) Low P/E

Apr 17

CEO

Xiaomin Xue (66 yo)

no data

Tenure

CN¥717,400

Compensatie

Mr. Xiaomin Xue is General Manager of Jilin Jian Yisheng Pharmaceutical Co., Ltd. He was Vice Chairman of Jilin Jian Yisheng Pharmaceutical Co., Ltd. until May 11, 2022.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Jian Tao Bi	Deputy GM	2.5yrs	CN¥527.30k	geen gegevens
Yisheng Zhang	Chairman of the Board	23.9yrs	CN¥1.05m	39.08% CN¥ 924.8m
Jianjun Qu	Non-Independent Director	7.1yrs	CN¥248.40k	geen gegevens
Xiaole Tong	Non-Independent Director	7.1yrs	CN¥279.00k	geen gegevens
Junyan Ye	Supervisor	7.1yrs	geen gegevens	geen gegevens
Qibin Chen	Independent Director	1.5yrs	CN¥33.30k	geen gegevens
Ming Li	Independent Director	5.5yrs	CN¥50.00k	geen gegevens
He Wang	Non-Independent Director	2.5yrs	CN¥279.00k	geen gegevens
Lirong Sun	Independent Director	2.5yrs	CN¥50.00k	geen gegevens
Yuchun Fang	Shareholder Supervisor	2.5yrs	geen gegevens	geen gegevens
Zhang Xin	Vice Chairman	2.5yrs	CN¥143.40k	geen gegevens

2.5yrs

Gemiddelde duur

46yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 002566 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.5 jaar), wat duidt op een nieuw bestuur.

Jilin Jian Yisheng Pharmaceutical Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Jilin Jian Yisheng Pharmaceutical Co., Ltd., Annual General Meeting, May 10, 2024

High number of new directors

High number of new directors

High number of new directors

High number of new directors

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.008 (vs CN¥0.033 in 3Q 2023)

Jilin Jian Yisheng Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 26, 2024

Investor sentiment improves as stock rises 18%

Now 23% overvalued after recent price rise

Second quarter 2024 earnings released: EPS: CN¥0.037 (vs CN¥0.057 in 2Q 2023)

Jilin Jian Yisheng Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 24, 2024

Now 20% overvalued after recent price rise

First quarter 2024 earnings released: EPS: CN¥0.064 (vs CN¥0.087 in 1Q 2023)

Jilin Jian Yisheng Pharmaceutical's (SZSE:002566) Earnings Are Weaker Than They Seem

Full year 2023 earnings released: EPS: CN¥0.29 (vs CN¥0.25 in FY 2022)

Jilin Jian Yisheng Pharmaceutical Co., Ltd., Annual General Meeting, May 10, 2024

Lacklustre Performance Is Driving Jilin Jian Yisheng Pharmaceutical Co., Ltd.'s (SZSE:002566) Low P/E

Investor sentiment deteriorates as stock falls 17%

Jilin Jian Yisheng Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Now 22% overvalued

Investor sentiment deteriorates as stock falls 20%

High number of new directors

Jilin Jian Yisheng Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 19, 2024

Third quarter 2023 earnings released: EPS: CN¥0.033 (vs CN¥0.05 in 3Q 2022)

Jilin Jian Yisheng Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Oct 27, 2023

New minor risk - Earnings quality

Second quarter 2023 earnings released: EPS: CN¥0.057 (vs CN¥0.05 in 2Q 2022)

Full year 2022 earnings released: EPS: CN¥0.25 (vs CN¥0.29 in FY 2021)

High number of new directors

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: CN¥0.05 (vs CN¥0.072 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.05 (vs CN¥0.041 in 2Q 2021)

Jilin Jian Yisheng Pharmaceutical Co., Ltd. Announces 2021 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on July 07, 2022

High number of new directors

Jilin Jian Yisheng Pharmaceutical Co., Ltd. Approves Cash Dividend for the Year 2021

High number of new directors

Jilin Jian Yisheng Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for 2021

Full year 2021 earnings released: EPS: CN¥0.29 (vs CN¥0.24 in FY 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.072 (vs CN¥0.065 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.041 (vs CN¥0.034 in 2Q 2020)

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS CN¥0.24 (vs CN¥0.23 in FY 2019)

Jilin Jian Yisheng Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Apr 17, 2021

New 90-day low: CN¥5.79

New 90-day low: CN¥6.00

New 90-day low: CN¥6.43

New 90-day low: CN¥6.80

New 90-day low: CN¥6.88

Third quarter earnings released

Jilin Jian Yisheng Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 24, 2020

New 90-day low: CN¥6.96

Earnings released

New 90-day high - CN¥7.68

Jilin Jian Yisheng Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 18, 2020

CEO

Tenure

Compensatie

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd